Insights on Multiple Myeloma Treatment Strategies

被引：36

作者：

Mateos, Maria-Victoria ^{[1
]}

Ludwig, Heinz ^{[2
]}

Bazarbachi, Ali ^{[3
]}

Beksac, Meral ^{[4
]}

Blade, Joan ^{[5
]}

Boccadoro, Mario ^{[6
]}

Cavo, Michele ^{[7
]}

Delforge, Michel ^{[8
]}

Dimopoulos, Meletios A. ^{[9
]}

Facon, Thierry ^{[10
]}

Geraldes, Catarina ^{[11
]}

Goldschmidt, Hartmut ^{[12
,13
]}

Hajek, Roman ^{[14
,15
]}

Hansson, Markus ^{[16
,17
]}

Jamroziak, Krzysztof ^{[18
]}

Leiba, Merav ^{[19
]}

Masszi, Tames ^{[20
]}

Mendeleeva, Larisa ^{[21
]}

O'Dwyer, Michael ^{[22
]}

Plesner, Torben ^{[23
,24
]}

San-Miguel, Jesus F. ^{[25
]}

Straka, Christian ^{[26
]}

van de Donk, Niels W. C. J. ^{[27
]}

Yong, Kwee ^{[28
]}

Zver, Samo ^{[29
]}

Moreau, Philippe ^{[30
]}

Sonneveld, Pieter ^{[31
]}

机构：

[1] Complejo Asistencial Univ Salamanca, Inst Invest Biomed Salamanca CAUSA IBSAL, Salamanca, Spain

[2] Wilhelminenspital Stadt Wien, Wilhelminen Canc Res Inst, Vienna, Austria

[3] Amer Univ Beirut, Dept Internal Med, Beirut, Lebanon

[4] Ankara Univ, Sch Med, Ankara, Turkey

[5] Inst Invest Biomed August Pi Sunyer IDIBAPS, Barcelona, Spain

[6] Univ Torino, Azienda Osped Univ Citta Salute & Sci Torino, Turin, Italy

[7] Bologna Univ, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[8] Univ Hosp Leuven, Leuven, Belgium

[9] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

[10] Hop Claude Huriez, Serv Malad Sang, Lille, France

[11] Hosp & Univ Ctr Coimbra, Coimbra, Portugal

[12] Univ Clin Heidelberg, Dept Internal Med 5, Heidelberg, Germany

[13] Natl Ctr Tumor Dis, Heidelberg, Germany

[14] Univ Hosp Ostrava, Dept Homatooncol, Ostrava, Czech Republic

[15] Univ Ostrava, Fac Med, Ostrava, Czech Republic

[16] Skane Univ Hosp, Dept Hematol, Lund, Sweden

[17] Lund Univ, Lund, Sweden

[18] Inst Hematol & Transfus Med, Warsaw, Poland

[19] Ben Gurion Univ Negev, Assuta Ashdod Univ Hosp, Fac Hlth Sci, Negev, Israel

[20] Semmelweis Univ, Dept Internal Med 3, Budapest, Hungary

[21] Minist Healthcare Russian Federat, Natl Res Ctr Hematol, Moscow, Russia

[22] Galway Univ Hosp, Galway, Ireland

[23] Vejie Hosp, Vejle, Denmark

[24] Univ Southern Denmark, Vejle, Denmark

[25] Clin Univ Navarre, CIBERONC, CIMA, IDISNA, Pamplona, Spain

[26] Klinikum Schwabing, Munich, Germany

[27] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, Amsterdam, Netherlands

[28] UCL, Canc Inst, London, England

[29] Univ Clin Ctr Ljubljana & Med Fac, Ljubljana, Slovenia

[30] Univ Nantes, Nantes, France

[31] Erasmus MC, Canc Inst, Dept Hematol, Rotterdam, Netherlands

来源：

HEMASPHERE | 2019年 / 3卷 / 01期

关键词：

STEM-CELL TRANSPLANTATION; LENALIDOMIDE PLUS DEXAMETHASONE; PROGRESSION-FREE SURVIVAL; LOW-DOSE DEXAMETHASONE; CONSOLIDATION THERAPY; GERIATRIC ASSESSMENT; FOLLOW-UP; BORTEZOMIB; MAINTENANCE; RISK;

D O I：

10.1097/HS9.0000000000000163

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The introduction of new agents and management strategies over the past decade has resulted in a major step change in treatment outcomes with deepening responses and increased survival for patients with multiple myeloma. In daily clinical practice, healthcare professionals are now faced with challenges including, optimal treatment sequencing and changing treatment goals. In light of this, a group of experts met to discuss diagnostic and treatment guidelines, examine current clinical practice, and consider how new clinical trial data may be integrated into the management of multiple myeloma in the future.

引用

页数：10

共 92 条

[1] T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Ali, Syed Abbas
Shi, Victoria
Maric, Irina
Wang, Michael
Stroncek, David F.
Rose, Jeremy J.
Brudno, Jennifer N.
Stetler-Stevenson, Maryalice
Feldman, Steven A.
Hansen, Brenna G.
Fellowes, Vicki S.
Hakim, Frances T.
Gress, Ronald E.
Kochenderfer, James N.
[J]. BLOOD, 2016, 128 (13) : 1688 - 1700
[2] [Anonymous], BLOOD S1
[3] [Anonymous], BLOOD S1
[4] [Anonymous], 2017, BLOOD S1
[5] [Anonymous], 2017, THESIS MOSCOW
[6] Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, Michel
Lauwers-Cances, Valerie
Hulin, Cyrille
Leleu, Xavier
Caillot, Denis
Escoffre, Martine
Arnulf, Bertrand
Macro, Margaret
Belhadj, Karim
Garderet, Laurent
Roussel, Murielle
Payen, Catherine
Mathiot, Claire
Fermand, Jean P.
Meuleman, Nathalie
Rollet, Sandrine
Maglio, Michelle E.
Zeytoonjian, Andrea A.
Weller, Edie A.
Munshi, Nikhil
Anderson, Kenneth C.
Richardson, Paul G.
Facon, Thierry
Avet-Loiseau, Herve
Harousseau, Jean-Luc
Moreau, Philippe
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14) : 1311 - 1320
[7] Auclair D, 2017, BLOOD, V130
[8] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
Badros, Ashraf
Hyjek, Elizabeth
Ma, Ning
Lesokhin, Alexander
Dogan, Ahmet
Rapoport, Aaron P.
Kocoglu, Mehmet
Lederer, Emily
Philip, Sunita
Milliron, Todd
Dell, Cameron
Goloubeva, Olga
Singh, Zeba
[J]. BLOOD, 2017, 130 (10) : 1189 - 1197
[9] Bahlis NJ, 2017, BLOOD, V130
[10] F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
Bartel, Twyla B.
Haessler, Jeff
Brown, Tracy L. Y.
Shaughnessy, John D., Jr.
van Rhee, Frits
Anaissie, Elias
Alpe, Terri
Angtuaco, Edgardo
Walker, Ronald
Epstein, Joshua
Crowley, John
Barlogie, Bart
[J]. BLOOD, 2009, 114 (10) : 2068 - 2076

← 1 2 3 4 5 6 7 8 9 10 →